#1 Clinical Trials Search in Europe

Gemcitabine

Gemcitabine is a chemotherapy drug that has shown promise in treating various types of cancer. This article explores recent clinical trials investigating gemcitabine’s effectiveness, either alone or in combination with other treatments, for cancers such as pancreatic cancer, lung cancer, and nasopharyngeal carcinoma. We’ll examine how researchers are working to improve gemcitabine’s efficacy and reduce side effects through new formulations and combination therapies.

Table of Contents

What is Gemcitabine?

Gemcitabine is a chemotherapy drug used to treat various types of cancer. It’s also known by its brand name Gemzar[1]. Gemcitabine belongs to a class of drugs called antimetabolites, which work by interfering with the growth of cancer cells[2].

How Gemcitabine Works

Gemcitabine works by killing rapidly dividing cells in the body, including cancer cells. It does this by interfering with the process of cell division, preventing cancer cells from growing and multiplying[3]. This mechanism of action makes gemcitabine effective against various types of cancer, but it can also affect healthy cells that divide quickly, which can lead to side effects.

Conditions Treated with Gemcitabine

Gemcitabine is used to treat several types of cancer, including:

  • Pancreatic cancer: Gemcitabine is commonly used to treat advanced or metastatic pancreatic cancer[4].
  • Bladder cancer: It’s used in the treatment of advanced or metastatic bladder cancer[5].
  • Non-small cell lung cancer: Gemcitabine can be part of the treatment regimen for this type of lung cancer.
  • Ovarian cancer: It’s sometimes used in combination with other drugs to treat ovarian cancer.
  • Breast cancer: Gemcitabine can be used in certain types of breast cancer treatment.
  • Biliary tract cancer: This includes cancers of the bile ducts and gallbladder[6].

How Gemcitabine is Administered

Gemcitabine is typically given as an intravenous (IV) infusion, which means it’s administered directly into a vein. The dosage and schedule can vary depending on the type of cancer being treated and other factors. Here are some common administration methods:

  • Weekly infusions for 2 or 3 weeks, followed by a week of rest[5].
  • Infusions on days 1 and 8 of a 21-day cycle[3].
  • Continuous infusion over 24 hours[4].

The exact schedule will be determined by your healthcare team based on your individual needs and response to treatment.

Gemcitabine in Combination Therapies

Gemcitabine is often used in combination with other cancer treatments to enhance its effectiveness. Some common combination therapies include:

  • Gemcitabine and cisplatin: This combination is used for bladder cancer and biliary tract cancers[6].
  • Gemcitabine and nab-paclitaxel (Abraxane): Used in the treatment of pancreatic cancer[1].
  • Gemcitabine and capecitabine (Xeloda): Another combination used in pancreatic cancer treatment[1].
  • Gemcitabine and radiation therapy: Sometimes used in locally advanced pancreatic cancer[7].

Potential Side Effects

Like all chemotherapy drugs, gemcitabine can cause side effects. Some common side effects include:

  • Fatigue
  • Nausea and vomiting
  • Loss of appetite
  • Low blood cell counts (which can increase risk of infection and bleeding)
  • Hair loss
  • Skin rash
  • Flu-like symptoms

Your healthcare team will monitor you closely for these side effects and can provide treatments to help manage them. It’s important to report any side effects you experience to your doctor.

Ongoing Research and Clinical Trials

Researchers are continually studying gemcitabine to find new ways to use it more effectively and to reduce its side effects. Some areas of ongoing research include:

  • Combining gemcitabine with new targeted therapies, such as the Wee1 inhibitor AZD1775, to enhance its effectiveness in pancreatic cancer[7].
  • Using gemcitabine in combination with immunotherapy drugs to boost the body’s immune response against cancer.
  • Exploring different dosing schedules to maximize effectiveness while minimizing side effects.
  • Investigating gemcitabine’s effectiveness in treating other types of cancer.

Clinical trials are an important way for researchers to study new treatments and combinations. If you’re interested in participating in a clinical trial involving gemcitabine, talk to your oncologist about what options might be available to you.

Aspect Details
Cancer Types Studied Pancreatic cancer, non-small cell lung cancer, nasopharyngeal carcinoma, advanced solid malignancies, malignant lymphomas
Common Combination Therapies Cisplatin, sorafenib, pemetrexed, lenalidomide
New Delivery Methods Oral formulations, ultrasound-assisted delivery
Primary Outcomes Measured Progression-free survival, overall survival, tumor response rates, safety and tolerability
Dosing Schedules Various, including weekly administration and 21-day cycles
Novel Approaches Combining with immunomodulatory drugs, exploring different dosing schedules

FAQ

  • What types of cancer is gemcitabine being studied for in clinical trials? Gemcitabine is being studied in clinical trials for several types of cancer, including pancreatic cancer, non-small cell lung cancer, nasopharyngeal carcinoma, and various advanced solid malignancies and lymphomas.
  • How is gemcitabine typically administered in these trials? In most trials, gemcitabine is administered intravenously, often on a weekly schedule. However, some studies are exploring oral formulations of gemcitabine to potentially improve patient convenience and drug effectiveness.
  • What are some common drugs gemcitabine is being combined with in clinical trials? Gemcitabine is being studied in combination with various drugs, including cisplatin, sorafenib, pemetrexed, and lenalidomide. These combinations aim to enhance the overall effectiveness of cancer treatment.
  • Are there any new delivery methods being explored for gemcitabine? Yes, researchers are investigating new delivery methods for gemcitabine, including oral formulations and ultrasound-assisted delivery to potentially increase drug uptake in tumors.
  • What are some of the primary outcomes researchers are looking at in gemcitabine clinical trials? Researchers are primarily examining outcomes such as progression-free survival, overall survival, tumor response rates, safety and tolerability, and in some cases, the immunomodulatory effects of gemcitabine in combination with other drugs.

Ongoing Clinical Trials on Gemcitabine

  • A Study of BMS-986504 Combined with Nab-Paclitaxel and Gemcitabine for Patients with Untreated Metastatic Pancreatic Cancer with MTAP Gene Deletion

    Recruiting

    4 1 1
    Investigated drugs:
    Austria Belgium Czechia Denmark France Germany +9

  • Study of gemcitabine, cisplatin, and pembrolizumab before and after surgery compared to surgery alone for patients with bile duct cancer

    Recruiting

    4 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study of MP0317 with durvalumab, gemcitabine and cisplatin combination therapy as first-line treatment for patients with advanced biliary tract cancer

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study of THIO and cemiplimab compared to chemotherapy in patients with advanced non-small cell lung cancer who have received two previous treatments

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Hungary Poland Portugal Romania Spain

  • A study of rilvegostomig, cisplatin, and gemcitabine compared to durvalumab and a drug combination for adults with advanced biliary tract cancer

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Italy The Netherlands Poland +1

  • A study of ACR-368 and gemcitabine for patients with endometrial cancer

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy Spain

  • Study of the safety and use of the Extroducer infusion catheter system for delivering gemcitabine to patients with unresectable locally advanced pancreatic cancer

    Recruiting

    1 1 1 1
    Investigated drugs:
    Sweden

  • Study comparing datopotamab deruxtecan with or without durvalumab to chemotherapy with pembrolizumab for patients with triple-negative breast cancer

    Recruiting

    3 1 1 1
    Investigated drugs:
    France Italy Poland Spain

  • Study of Izalontamab Brengitecan Compared to Platinum-Based Chemotherapy for Patients with Metastatic Urothelial Cancer After Immunotherapy

    Recruiting

    4 1 1 1
    Investigated drugs:
    Austria Belgium Czechia France Germany Ireland +5

  • A Study of Evorpacept Combined with Trastuzumab and Chemotherapy for Patients with Metastatic HER2-Positive Breast Cancer

    Recruiting

    2 1 1 1
    Investigated drugs:
    France Italy Spain

Glossary

  • Gemcitabine: A chemotherapy drug used to treat various types of cancer, including pancreatic, lung, and breast cancer. It works by interfering with the growth of cancer cells.
  • Clinical trial: A research study that tests new medical treatments, interventions, or tests in human volunteers to evaluate their safety and effectiveness.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives with cancer without the disease getting worse.
  • Overall survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • Metastatic: Cancer that has spread from its original site to other parts of the body.
  • Inoperable: A condition that cannot be treated effectively through surgery, often due to the location or extent of the disease.
  • Immunomodulatory: Capable of modifying or regulating immune functions in the body.
  • Adverse event: Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Maximum Tolerated Dose (MTD): The highest dose of a drug or treatment that does not cause unacceptable side effects.
  • Pharmacokinetics (PK): The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • RECIST criteria: Response Evaluation Criteria In Solid Tumors – a standard way to measure how well a cancer patient responds to treatment.
  • Dose-limiting toxicity (DLT): Side effects of a drug that are severe enough to prevent an increase in dose or require a decrease in dose.

References

  1. https://clinicaltrials.gov/study/NCT02581501
  2. https://clinicaltrials.gov/study/NCT00005577
  3. https://clinicaltrials.gov/study/NCT01622660
  4. https://clinicaltrials.gov/study/NCT01526135
  5. https://clinicaltrials.gov/study/NCT03061630
  6. https://clinicaltrials.gov/study/NCT00919061
  7. https://clinicaltrials.gov/study/NCT02037230